Literature DB >> 31903101

Cytotoxic effects of gemcitabine-loaded solid lipid nanoparticles in pancreatic cancer cells.

Kevin O Affram1, Taylor Smith1, Edward Ofori2, Sunil Krishnan3, Patrick Underwood4, Jose G Trevino4, Edward Agyare1.   

Abstract

This study investigated the cytotoxic effects of gemcitabine-loaded solid lipid nanoparticle (Gem-SLN) on the patient-derived primary pancreatic cancer cell lines (PPCL-46) and MiaPaCa-2. Different SLN formulations were prepared from glyceryl monostearate (GMS), polysorbate 80 (Tween® 80) and poloxamer 188 (Pol 188) as surfactants using a cold homogenization method. Gem-SLN was characterized for particle size and charge distribution, entrapment efficiency and loading capacity. Fourier Transform Infra-Red (FTIR) spectroscopy was used to verify Gem and SLN interaction while differential scanning calorimetry (DSC) was used to acquire thermodynamic information on Gem-SLN. Cytotoxicity studies was conducted on PPCL-46 cells and Mia-PaCa-2 cells. Among the different Gem-SLN formulations prepared, Gem-SLN15 was selected based on entrapment efficiency (EE) of Gem, loading efficiency of Gem, cytotoxicity and rate of Gem release. Growth inhibition of Gem-SLN15-treated PPCL-46 culture (IC50 (2D) =27± 5 μM; IC50 (3D) = 66 ± 2 μM) was remarkably higher than gemcitabine hydrochloride (GemHCl)-treated PPCL-46 culture (IC50 (2D) =126±3 μM; IC50 (3D) =241±3 μM). Similar trend of higher Gem-SLN15 inhibition in MiaPaCa-2 culture was found (IC50 (2D) =56±16 μM; IC50 (3D) =127±4 μM) compared with GemHCl-treated Mia-PaCa-2 culture (IC50 (2D) =188±46 μM; IC50 (3D) =254±52 μM). The anticancer activity of Gem-SLN15 was significantly more effective than GemHCl in PPCL-46 compared to Mia-PaCa-2 cancer cells. Schematic diagram for preparation of Gem-SLN through cold homogenization and methods for characterization and in-vitro studies.

Entities:  

Keywords:  Gemcitabine; in-vitro release kinetics; primary pancreatic cancer; solid lipid nanoparticle; spheroids

Year:  2019        PMID: 31903101      PMCID: PMC6941746          DOI: 10.1016/j.jddst.2019.101374

Source DB:  PubMed          Journal:  J Drug Deliv Sci Technol        ISSN: 1773-2247            Impact factor:   3.981


  41 in total

Review 1.  Kinetic modeling on drug release from controlled drug delivery systems.

Authors:  Suvakanta Dash; Padala Narasimha Murthy; Lilakanta Nath; Prasanta Chowdhury
Journal:  Acta Pol Pharm       Date:  2010 May-Jun       Impact factor: 0.330

2.  Hypoxia Responsive, Tumor Penetrating Lipid Nanoparticles for Delivery of Chemotherapeutics to Pancreatic Cancer Cell Spheroids.

Authors:  Prajakta Kulkarni; Manas K Haldar; Preeya Katti; Courtney Dawes; Seungyong You; Yongki Choi; Sanku Mallik
Journal:  Bioconjug Chem       Date:  2016-07-27       Impact factor: 4.774

3.  Trends in the treatment and outcome of pancreatic cancer in the United States.

Authors:  Nancy N Baxter; Bryan A Whitson; Todd M Tuttle
Journal:  Ann Surg Oncol       Date:  2007-01-17       Impact factor: 5.344

Review 4.  Apoptosis: a review of programmed cell death.

Authors:  Susan Elmore
Journal:  Toxicol Pathol       Date:  2007-06       Impact factor: 1.902

5.  Transport properties of pancreatic cancer describe gemcitabine delivery and response.

Authors:  Eugene J Koay; Mark J Truty; Vittorio Cristini; Ryan M Thomas; Rong Chen; Deyali Chatterjee; Ya'an Kang; Priya R Bhosale; Eric P Tamm; Christopher H Crane; Milind Javle; Matthew H Katz; Vijaya N Gottumukkala; Marc A Rozner; Haifa Shen; Jeffery E Lee; Huamin Wang; Yuling Chen; William Plunkett; James L Abbruzzese; Robert A Wolff; Gauri R Varadhachary; Mauro Ferrari; Jason B Fleming
Journal:  J Clin Invest       Date:  2014-03-10       Impact factor: 14.808

6.  Biophysical studies on chitosan-coated liposomes.

Authors:  Mohsen M Mady; Mirhane M Darwish; Safaa Khalil; Wafaa M Khalil
Journal:  Eur Biophys J       Date:  2009-08-02       Impact factor: 1.733

7.  Rapid determination of gemcitabine in plasma and serum using reversed-phase HPLC.

Authors:  Christian Lanz; Martin Früh; Wolfgang Thormann; Thomas Cerny; Bernhard H Lauterburg
Journal:  J Sep Sci       Date:  2007-08       Impact factor: 3.645

8.  Formulation and evaluation of solid lipid nanoparticles of ramipril.

Authors:  P Ekambaram; Hasan Sathali A Abdul
Journal:  J Young Pharm       Date:  2011-07

9.  Formulation and characterization of curcuminoids loaded solid lipid nanoparticles.

Authors:  Waree Tiyaboonchai; Watcharaphorn Tungpradit; Pinyupa Plianbangchang
Journal:  Int J Pharm       Date:  2007-01-09       Impact factor: 5.875

Review 10.  Overcoming tumor cell chemoresistance using nanoparticles: lysosomes are beneficial for (stearoyl) gemcitabine-incorporated solid lipid nanoparticles.

Authors:  Zhe Chen; Yuanqiang Zheng; Yanchun Shi; Zhengrong Cui
Journal:  Int J Nanomedicine       Date:  2018-01-09
View more
  5 in total

1.  In Vitro Assays for Nanoparticle-Cancer Cell Interaction Studies.

Authors:  Tomás Bauleth-Ramos; Bruno Sarmento
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 2.  Nanocarrier drug resistant tumor interactions: novel approaches to fight drug resistance in cancer.

Authors:  Aleksandra Benko; David Medina-Cruz; Ada Vernet-Crua; Catherine P O'Connell; Małgorzata Świętek; Hamed Barabadi; Muthupandian Saravanan; Thomas J Webster
Journal:  Cancer Drug Resist       Date:  2021-06-19

Review 3.  Recent Advances in Lipid-Based Nanosystems for Gemcitabine and Gemcitabine-Combination Therapy.

Authors:  Saffiya Habib; Moganavelli Singh
Journal:  Nanomaterials (Basel)       Date:  2021-02-27       Impact factor: 5.076

Review 4.  Combining Nanotechnology and Gas Plasma as an Emerging Platform for Cancer Therapy: Mechanism and Therapeutic Implication.

Authors:  Milad Rasouli; Nadia Fallah; Sander Bekeschus
Journal:  Oxid Med Cell Longev       Date:  2021-10-27       Impact factor: 6.543

Review 5.  Polymeric Nanoparticles in Cancer Chemotherapy: A Narrative Review.

Authors:  Hossein Ali Yousefi Rizi; Dong Hoon Shin; Shima Yousefi Rizi
Journal:  Iran J Public Health       Date:  2022-02       Impact factor: 1.479

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.